Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
REPAY Stock Rises After Visa Platform Connect Collaboration 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Add as a preferred source on Google
NEW YORK, May 04, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of investors who purchased Myriad Genetics, Inc. ("Myriad") (NASDAQ:MYGN) securities between August 13, 2014 and March 12, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/myriad-genetics-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad’s public statements were materially false and misleading at all relevant times. On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.”
If you suffered a loss in Myriad you have until June 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/myriad-genetics-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
